These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37688574)

  • 1. CDKL5-mediated developmental tuning of neuronal excitability and concomitant regulation of transcriptome.
    Liao W; Lee KZ
    Hum Mol Genet; 2023 Nov; 32(23):3276-3298. PubMed ID: 37688574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKL5 deficiency in forebrain glutamatergic neurons results in recurrent spontaneous seizures.
    Wang HT; Zhu ZA; Li YY; Lou SS; Yang G; Feng X; Xu W; Huang ZL; Cheng X; Xiong ZQ
    Epilepsia; 2021 Feb; 62(2):517-528. PubMed ID: 33400301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aged heterozygous Cdkl5 mutant mice exhibit spontaneous epileptic spasms.
    Mulcahey PJ; Tang S; Takano H; White A; Davila Portillo DR; Kane OM; Marsh ED; Zhou Z; Coulter DA
    Exp Neurol; 2020 Oct; 332():113388. PubMed ID: 32585155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of microglia overactivation restores neuronal survival in a mouse model of CDKL5 deficiency disorder.
    Galvani G; Mottolese N; Gennaccaro L; Loi M; Medici G; Tassinari M; Fuchs C; Ciani E; Trazzi S
    J Neuroinflammation; 2021 Jul; 18(1):155. PubMed ID: 34238328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKL5 deficiency in adult glutamatergic neurons alters synaptic activity and causes spontaneous seizures via TrkB signaling.
    Zhu ZA; Li YY; Xu J; Xue H; Feng X; Zhu YC; Xiong ZQ
    Cell Rep; 2023 Oct; 42(10):113202. PubMed ID: 37777961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AMPA Receptor Dysregulation and Therapeutic Interventions in a Mouse Model of CDKL5 Deficiency Disorder.
    Yennawar M; White RS; Jensen FE
    J Neurosci; 2019 Jun; 39(24):4814-4828. PubMed ID: 30952813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mGluR5 PAMs rescue cortical and behavioural defects in a mouse model of CDKL5 deficiency disorder.
    Gurgone A; Pizzo R; Raspanti A; Chiantia G; Devi S; Comai D; Morello N; Pilotto F; Gnavi S; Lupori L; Mazziotti R; Sagona G; Putignano E; Nocentini A; Supuran CT; Marcantoni A; Pizzorusso T; Giustetto M
    Neuropsychopharmacology; 2023 May; 48(6):877-886. PubMed ID: 35945276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early-onset brain alterations during postnatal development in a mouse model of CDKL5 deficiency disorder.
    Tassinari M; Uguagliati B; Trazzi S; Cerchier CB; Cavina OV; Mottolese N; Loi M; Candini G; Medici G; Ciani E
    Neurobiol Dis; 2023 Jun; 182():106146. PubMed ID: 37164289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacotherapy with sertraline rescues brain development and behavior in a mouse model of CDKL5 deficiency disorder.
    Fuchs C; Gennaccaro L; Ren E; Galvani G; Trazzi S; Medici G; Loi M; Conway E; Devinsky O; Rimondini R; Ciani E
    Neuropharmacology; 2020 May; 167():107746. PubMed ID: 31469994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A GABA
    Gennaccaro L; Fuchs C; Loi M; Roncacè V; Trazzi S; Ait-Bali Y; Galvani G; Berardi AC; Medici G; Tassinari M; Ren E; Rimondini R; Giustetto M; Aicardi G; Ciani E
    Neurobiol Dis; 2021 Jun; 153():105304. PubMed ID: 33621640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autistic-relevant behavioral phenotypes of a mouse model of cyclin-dependent kinase-like 5 deficiency disorder.
    Mottolese N; Coiffard O; Ferraguto C; Manolis A; Ciani E; Pietropaolo S
    Autism Res; 2024 Sep; 17(9):1742-1759. PubMed ID: 39234879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. X-linked cellular mosaicism underlies age-dependent occurrence of seizure-like events in mouse models of CDKL5 deficiency disorder.
    Terzic B; Cui Y; Edmondson AC; Tang S; Sarmiento N; Zaitseva D; Marsh ED; Coulter DA; Zhou Z
    Neurobiol Dis; 2021 Jan; 148():105176. PubMed ID: 33197557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced hippocampal LTP but normal NMDA receptor and AMPA receptor function in a rat model of CDKL5 deficiency disorder.
    Simões de Oliveira L; O'Leary HE; Nawaz S; Loureiro R; Davenport EC; Baxter P; Louros SR; Dando O; Perkins E; Peltier J; Trost M; Osterweil EK; Hardingham GE; Cousin MA; Chattarji S; Booker SA; Benke TA; Wyllie DJA; Kind PC
    Mol Autism; 2024 Jun; 15(1):28. PubMed ID: 38877552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
    Demarest ST; Olson HE; Moss A; Pestana-Knight E; Zhang X; Parikh S; Swanson LC; Riley KD; Bazin GA; Angione K; Niestroj LM; Lal D; Juarez-Colunga E; Benke TA
    Epilepsia; 2019 Aug; 60(8):1733-1742. PubMed ID: 31313283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Providing quality care for people with CDKL5 deficiency disorder: A European expert panel opinion on the patient journey.
    Amin S; Møller RS; Aledo-Serrano A; Arzimanoglou A; Bager P; Jóźwiak S; Kluger GJ; López-Cabeza S; Nabbout R; Partridge CA; Schubert-Bast S; Specchio N; Kälviäinen R
    Epilepsia Open; 2024 Jun; 9(3):832-849. PubMed ID: 38450883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CDKL5 deficiency predisposes neurons to cell death through the deregulation of SMAD3 signaling.
    Fuchs C; Medici G; Trazzi S; Gennaccaro L; Galvani G; Berteotti C; Ren E; Loi M; Ciani E
    Brain Pathol; 2019 Sep; 29(5):658-674. PubMed ID: 30793413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder.
    Voronin G; Narasimhan J; Gittens J; Sheedy J; Lipari P; Peters M; DeMarco S; Cao L; Varganov Y; Kim MJ; Pear L; Fotouh E; Sinha S; Ray B; Wu MC; Yalamanchili P; Southgate C; Pick J; Saadipour K; Jung S; Lee J; Mollin A; Welch EM; Wu Z; Weetall M
    Mol Ther; 2024 Oct; 32(10):3331-3345. PubMed ID: 39033321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Voluntary Running Improves Behavioral and Structural Abnormalities in a Mouse Model of CDKL5 Deficiency Disorder.
    Mottolese N; Uguagliati B; Tassinari M; Cerchier CB; Loi M; Candini G; Rimondini R; Medici G; Trazzi S; Ciani E
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-Dependent Kinase-Like 5 (CDKL5): Possible Cellular Signalling Targets and Involvement in CDKL5 Deficiency Disorder.
    Katayama S; Sueyoshi N; Inazu T; Kameshita I
    Neural Plast; 2020; 2020():6970190. PubMed ID: 32587608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
    Trovò L; Fuchs C; De Rosa R; Barbiero I; Tramarin M; Ciani E; Rusconi L; Kilstrup-Nielsen C
    Neurobiol Dis; 2020 May; 138():104791. PubMed ID: 32032735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.